The findings from this exploratory phase II trial serve as a proof-of-concept in head and neck cancer, providing impetus for additional clinical trials to investigate the potential clinical application advantages of this uPAR-targeting OMI agent in the surgical management of oral and oropharyngeal cancer. Here, PLAUR is linked to oropharynx cancer.